Market flat; takeover offers boost THL, Santos
Bourse operator faces ASIC inquiry over ‘repeated, serious failures’. Israeli strike success boosts Wall Street futures: IG. National interest of Santos deal up to Chalmers: Coalition.
Bourse operator faces ASIC inquiry over ‘repeated, serious failures’. Israeli strike success boosts Wall Street futures: IG. National interest of Santos deal up to Chalmers: Coalition.
A spike in oil and gold producing shares was not enough to lift the ASX200 on Friday as investors fear the fallout from the Iran-Israel crisis.
Crude prices lift as strikes on Iran send commodities higher. Rio’s jointly-owned Tomago smelter in rescue talks. Accent smashed on profit warning. Woodside, Labor extend NW Shelf consultation.
A spike in crude oil and gold was not enough to lift the ASX 200 as the banks slid during trading on Thursday.
Environment Minister Watt approves Woodside’s four-decade extension of WA project. Economists tip two more RBA rate cuts after April inflation print. MinRes downgrade weighs.
Aussies hoping for back-to-back rate cuts have received unwelcome news after the inflation figures for April were released.
Aussies hoping for back-to-back rate cuts have received unwelcome news after the inflation figures for April were released.
The ASX 200 is closing in on record high as bullish sentiment in the Australian market persists amid unstable global conditions.
Market closes at three-month high. Murray Watt makes ‘right sounds’ before decision on Woodside’s $30bn NW Shelf expansion. AMP sued for alleged excessive fees.
Investors back WiseTech’s $3bn e2open deal. No taxpayer bailout for Healthscope: Butler. Deep Yellow, Paladin, Boss top gainers on US president’s nuclear focus. AUD at six-month high as US dollar falls. Miss on earnings weighs on Elders.
An Aussie influencer has revealed how he lost $6.2 million in a Bali scam.
Australia’s sharemarket dipped after setting a 50-day high, with growing unease over US spending plans sparking a cautious turn among global investors.
A breakthrough drug expected to give back years to hundreds of thousands of Australians suffering through a debilitating disease has been approved.
One of Australia’s biggest banks is reportedly about to swing the axe on an estimated 1500 jobs in a massive redundancy cull.
Original URL: https://www.thechronicle.com.au/business/markets/page/6